Value
5.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 5.0 |
MPLT · Why this verdict
Why MapLight Therapeutics (MPLT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
MapLight Therapeutics shows weak fundamental quality, extreme insider selling, and a streak of earnings misses, though an overbought bounce shows some near-term buying interest.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company has missed EPS estimates in all of its last 3 reported quarters by a wide average margin. Earnings | The company should deliver at least one inline or beat quarter in its next 2 reports. | ↑Improving |
| CounterBiotech clinical-stage companies often have volatile, hard-to-model EPS, so misses may reflect estimate noise rather than business deterioration. | ||
The business exhibits weak fundamental quality, with negative free cash flow, no competitive moat, and a weak Piotroski F-Score of 2 out of 9. Quality breakdown | The quality score should rise above the engine's 4.0 floor as the business stabilizes financially. | →Stable |
| CounterOverbought momentum with rising volume accumulation points to near-term buying interest that could persist regardless of weak fundamentals. | ||
Insiders have sold an extreme amount of stock relative to market capitalization, signaling reduced insider confidence. Insider | Insider selling intensity should fall to a non-extreme level below 0.5% of market cap over the next quarter. | →Stable |
| CounterInsider sales can reflect routine diversification or pre-scheduled selling plans (Rule 10b5-1) rather than a fresh negative view of the business. | ||
The current rally looks overbought and characteristic of a bounce within a broader downtrend, which historically resolves back downward. Momentum breakdown | RSI should cool back toward 50 or below within a few weeks without a violent breakdown. | Tripped↓Deteriorating |
| CounterRising volume accumulation suggests genuine buying interest rather than a purely technical, unsustainable bounce. | ||
The company has missed EPS estimates in all of its last 3 reported quarters by a wide average margin.
↑ImprovingEarnings
- Expectation
- The company should deliver at least one inline or beat quarter in its next 2 reports.
CounterBiotech clinical-stage companies often have volatile, hard-to-model EPS, so misses may reflect estimate noise rather than business deterioration.
The business exhibits weak fundamental quality, with negative free cash flow, no competitive moat, and a weak Piotroski F-Score of 2 out of 9.
→StableQuality breakdown
- Expectation
- The quality score should rise above the engine's 4.0 floor as the business stabilizes financially.
CounterOverbought momentum with rising volume accumulation points to near-term buying interest that could persist regardless of weak fundamentals.
Insiders have sold an extreme amount of stock relative to market capitalization, signaling reduced insider confidence.
→StableInsider
- Expectation
- Insider selling intensity should fall to a non-extreme level below 0.5% of market cap over the next quarter.
CounterInsider sales can reflect routine diversification or pre-scheduled selling plans (Rule 10b5-1) rather than a fresh negative view of the business.
The current rally looks overbought and characteristic of a bounce within a broader downtrend, which historically resolves back downward.
Tripped↓DeterioratingMomentum breakdown
- Expectation
- RSI should cool back toward 50 or below within a few weeks without a violent breakdown.
CounterRising volume accumulation suggests genuine buying interest rather than a purely technical, unsustainable bounce.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
2.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 4.5 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
Sentiment
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.5 |
| Analyst rating | 8.5 |
| Price target | 7.7 |
- ▸LLM news sentiment: +0.70 (n=2)
- ▸Analyst upside: 20%
Insider
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 7.1 |
| notable moves | 7.0 |
- ▸Heavy insider selling — $17,605,219 (1.100% of mkt cap)
Peer rank
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.6 |
| growth rank | 5.0 |
Technical
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.8 |
| support resistance | 4.8 |
| 52w position | 7.7 |
| gap | 6.0 |
Risk (lower is worse)
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.1 |
| days to cover | 4.9 |
| volatility | 0.0 |
| put call | 3.3 |
| implied vol | 0.0 |
| debt equity | 9.9 |
- ▸High IV: 381%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 6.0 |
- ▸Earnings concerns: 0B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (4)
- NEWS_BOOST:ANALYST:0.70
- EARNINGS_PROXIMITY:21d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (3)
- MOMENTUM:2.0<4.5
- ASYMMETRY:0.3<1.5@spot
- INSIDER:1.10%=EXTREME
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.32
Upside
+4.8%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 47 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.0<4.5 outcome against Sentiment at 8.2 and asymmetric R:R of 0.32.
The strongest dimensions are Sentiment at 8.2, Technical at 6.1, and Value at 5.0; the weakest are Quality at 1.6, Momentum at 2.0, and Catalyst at 3.2. The V9 engine flagged 3 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.32 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Weak Fundamental Quality
Trip ifQuality score rises above 4.0, clearing the floor, within 2 consecutive quarters.
- P2Extreme Insider Selling
Trip ifInsider selling as a percent of market cap falls below 0.5% over the next 90 days.
- P3Earnings Miss Streak
Trip ifEPS surprise stays above 0% for at least 2 consecutive quarters.
- P4Overbought Bear Rally RiskTripped
Trip ifRSI falls below 50 within 60 days without a price decline exceeding 20%.